Isomorphic Labs has raised a whopping $600 million to refine its artificial intelligence-powered drug discovery engine, advance its pipeline, and expand its headcount in its first external funding ...

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.

Google parent Alphabet has drawn on its DeepMind artificial intelligence division to form a drug discovery unit that it calls Isomorphic Labs. The UK-registered company will be able to tap into ...

Google DeepMind, the artificial intelligence company behind the popular AlphaFold tool, has published the next generation of the application’s protein structure prediction software. The new tool can ...